The response to anti-TNF-α treatment: Gene regulation at the bedside

Rheumatology

Volumn 44, Issue 6, 2005, Pages 705-707

  de Vries, Niek ^a   Tak, P P ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; INFLIXIMAB; LYMPHOTOXIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER; DNA; IMMUNOGLOBULIN G; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ALLELE; DNA SEQUENCE; DRUG MECHANISM; DRUG TARGETING; EDITORIAL; GENE CONTROL; GENOTYPE; HLA SYSTEM; HUMAN; PATIENT SELECTION; PHARMACOGENETICS; POPULATION GENETICS; PRIORITY JOURNAL; RACE DIFFERENCE; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TUBERCULOSIS; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENETICS; NOTE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; DNA; GENE EXPRESSION REGULATION; HUMANS; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 24944560598     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keh662     Document Type: Editorial

References (23)

1. Weinblatt ME, Keystone EC, Furst DE et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 2003;48:35-45.
2. Genovese MC, Bathon JM, Martin RW et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46:1443-50.
3. Lipsky PE, van der Heijde DM, St Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
4. Tracey KJ, Cerami A. Tumor necrosis factor, other cytokines and disease. Annu Rev Cell Biol 1993;9:317-43.
5. Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 2001;11:372-7.
6. Pennisi E. Searching for the genome's second code. Science 2004;306:632-5.
7. Anderson P. Post-transcriptional regulation of tumour necrosis factor alpha production. Ann Rheum Dis 2000;59(Suppl. 1):i3-5.
8. Kang CP, Lee KW, Yoo DH, Kang C, Bae SC. The influence of a polymorphism at position -857 of the tumour necrosis factor α gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology 2005;44:547-52.
9. van Vollenhoven RF, Klareskog L. Clinical responses to tumor necrosis factor alpha antagonists do not show a bimodal distribution: Data from the Stockholm tumor necrosis factor alpha followup registry. Arthritis Rheum 2003;48:1500-3.
10. van Heel DA, Udalova IA, De Silva AP et al. Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF(-kappa)B transcription factors. Hum Mol Genet 2002;11:1281-9.
11. Mugnier B, Balandraud N, Darque A, Roudier C, Roudier J, Reviron D. Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum 2003;48:1849-52.
12. Balog A, Klausz G, Gal J et al. Investigation of the prognostic value of TNF-alpha gene polymorphism among patients treated with infliximab, and the effects of infliximab therapy on TNF-alpha production and apoptosis. Pathobiology 2004;71:274-80.
13. Criswell LA, Lum RF, Turner KN et al. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum 2004;50:2750-6.
14. Padyukov L, Lampa J, Heimburger M et al. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis 2003;62:526-9.
15. Martinez A, Salido M, Bonilla G et al. Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients. Arthritis Rheum 2004;50:1077-82.
16. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997;94:3195-9.
17. Knight JC, Keating BJ, Rockett KA, Kwiatkowski DP. In vivo characterization of regulatory polymorphisms by allele-specific quantification of RNA polymerase loading. Nat Genet 2003;33:469-75.
18. Bayley JP, Ottenhoff TH, Verweij CL. Is there a future for TNF promoter polymorphisms? Genes Immun 2004;5:315-29.
19. Baseggio L, Bartholin L, Chantome A, Charlot C, Rimokh R, Salles G. Allele-specific binding to the -308 single nucleotide polymorphism site in the tumour necrosis factor-alpha promoter. Eur J Immunogenet 2004;31:15-9.
20. Bouma G, Crusius JB, Oudkerk Pool M et al. Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. Scand J Immunol 1996;43:456-63.
21. Louis E, Franchimont D, Piron A et al. Tumour necrosis factor (TNF) gene polymorphism, influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 1998;113:401-6.
22. Enard W, Khaitovich P, Klose J et al. Intra- and interspecific variation in primate gene expression patterns. Science 2002;296:340-3.
23. Udalova IA, Richardson A, Denys A et al. Functional consequences of a polymorphism affecting NF-kappaB p50-p50 binding to the TNF promoter region. Mol Cell Biol 2000;20:9113-9.